All News

The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.

At the 2023 American Thoracic Society International Conference a symposium focused on common comorbidities seen with COPD, their management, and research needs.

Your daily dose of clinical news you may have missed.

New study found that patients living in urban areas were more likely to meet all aspects of key metrics of diabetes care.

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Your daily dose of clinical news you may have missed.

Brixadi is the first and only long-acting buprenorphine injectable that is available in both weekly and monthly doses.

The AAFP and other national medical groups endorsed the warning from Surgeon General Murthy that social media is fueling the mental health crisis among young Americans.

A recent CDC report showed that approximately 20% of Americans experienced chronic pain in 2021 and certain groups were most vulnerable. Details in our new slideshow.

Your daily dose of clinical news you may have missed.

In a unique pharmacodynamic study, nalmefene demonstrated rapid reversal of respiratory depression from the synthetic opioid remifentanil and sustained duration of action.

Medical director of the NFID William Schaffner, MD, discusses the research behind the FDA's decision to approve the first-ever RSV vaccine.

Efficacy of the daily pill met the standard now established by the once-weekly injection of 15% loss of baseline bodyweight in adults with overweight or obesity, says Novo Nordisk.

Your daily dose of clinical news you may have missed.

A nationally recognized obesity expert discusses mental health in women with obesity.

The findings contradict published clinical guidelines that warn against use of estrogen-containing birth control by women who have migraine with aura.

Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.

Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.